Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Transdermal drug delivery pharmaceutical reports third quarter EPS of $0.11
December 12th, 2004
Noven Pharmaceuticals, Inc. (NOVN) announced financial results for the quarter and 9 months ended September 30, 2004, provided an update on its business, and confirmed prior financial guidance for full-year 2004. "Third quarter results at our Novogyne joint venture reflect our continued leadership position in the transdermal hormone therapy ("HT") market," said Robert C. Strauss, Noven president, CEO and chairman. Noven's net revenues for the quarter ended September 30, 2004 were $10.1 million, an 11% increase over the $9.1 million reported in the quarter ended September 30, 2003. Net revenues for the 2003 quarter reflected the establishment of a...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
